VCM
VNDA icon

Versant Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Versant Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.1K Buy
2,474
+57
+2% +$306 ﹤0.01% 2196
2026
Q2 		$14.8K Buy
2,417
+55
+2% +$359 ﹤0.01% 2081
2026
Q1 		$16.3K Hold
2,362
– – ﹤0.01% 1915
2025
Q4 		$20.8K Buy
+2,362
New +$13K ﹤0.01% 1613
2025
Q2 		– Sell
-87
Closed -$399 – 2736
2025
Q1 		$399 Sell
87
-484
-85% -$2.26K ﹤0.01% 2427
2024
Q4 		$2.73K Buy
571
+547
+2,279% +$2.63K ﹤0.01% 1982
2024
Q3 		$113 Hold
24
– – ﹤0.01% 1982
2024
Q2 		$136 Hold
24
– – ﹤0.01% 1922
2024
Q1 		$99 Sell
24
-238
-91% -$953 ﹤0.01% 1862
2023
Q4 		$1.11K Buy
262
+22
+9% +$89 ﹤0.01% 1483
2023
Q3 		$1.04K Buy
240
+66
+38% +$367 ﹤0.01% 1515
2023
Q2 		$1.15K Hold
174
– – ﹤0.01% 1552
2023
Q1 		$1.17K Sell
174
-661
-79% -$4.65K ﹤0.01% 1405
2022
Q4 		$6.17K Sell
835
-27
-3% -$263 ﹤0.01% 812
2022
Q3 		$9K Buy
862
+5
+0.6% +$53 ﹤0.01% 690
2022
Q2 		$9K Buy
857
+109
+15% +$1.13K ﹤0.01% 702
2022
Q1 		$8K Sell
748
-37
-5% -$486 ﹤0.01% 760
2021
Q4 		$12K Buy
785
+34
+5% +$592 ﹤0.01% 672
2021
Q3 		$13K Sell
751
-91
-11% -$1.59K ﹤0.01% 628
2021
Q2 		$18K Sell
842
-366
-30% -$6.55K 0.01% 523
2021
Q1 		$18K Buy
1,208
+147
+14% +$2.38K 0.01% 596
2020
Q4 		$13K Buy
1,061
+7
+0.7% +$84 0.01% 660
2020
Q3 		$10K Buy
1,054
+270
+34% +$2.89K ﹤0.01% 669
2020
Q2 		$8K Sell
784
-122
-13% -$1.38K ﹤0.01% 712
2020
Q1 		$9K Buy
+906
New +$11.2K ﹤0.01% 595

Other funds holding VNDA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
CFS
CGC Financial Services Lake Oswego, Oregon $451M AUM 11.72% 1-Year Est. Return

Versant Capital Management's VNDA Position: Q3 2026 in Review

Versant Capital Management increased its Vanda Pharmaceuticals (VNDA) stake by 2.4% in Q3 2026, buying an estimated $306 and bringing the position to 2,474 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

Versant Capital Management first reported a position in VNDA in Q1 2020 and has held it in 25 quarters since. The position peaked at $20.8K in Q4 2025. 9 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

  • Versant Capital Management held 2,474 shares of Vanda Pharmaceuticals worth $12.1K as of Q3 2026.
  • Versant Capital Management bought 57 Vanda Pharmaceuticals shares in Q3 2026, an estimated $306.
  • Vanda Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2196 holding.
  • Versant Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Versant Capital Management's Vanda Pharmaceuticals position peaked at $20.8K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.